Avila J L, Rojas M, Galili U
Instituto de Biomedicina, Caracas, Venezuela.
J Immunol. 1989 Apr 15;142(8):2828-34.
Anti-Gal is a natural antibody present in unusually high concentrations in human sera. It constitutes as much as 1% of circulating IgG and displays a distinct specificity for the Gal alpha 1----3Gal carbohydrate epitope. In the present study, we have found in the sera of patients with Chagas' disease and Leishmania infection anti-Gal titers 10- and 16-fold higher than that of healthy or bacteria-infected individuals. This increase in anti-Gal titer seemed to be the result of a specific immune response toward parasitic Gal alpha 1----3Gal epitopes. Binding studies of affinity chromatography-purified anti-Gal antibodies to Trypanosoma cruzi and American Leishmania parasites indeed demonstrated the presence of Gal alpha 1----3Gal epitopes on these parasites. This finding was supported by the observed binding to the parasites of two additional Gal alpha 1----3Gal recognizing molecules: the mAb Gal-13, and the lectin, Bandeiraea simplicifolia I B4. Furthermore, the binding of both anti-Gal antibody and of the B. simplicifolia I B4 lectin could be inhibited by galactose, and not glucose. In addition, removal of the terminal alpha-galactosyl residues from the parasites by pretreatment with alpha-galactosidase, or the oxidation of the binding epitopes by periodate prevented the subsequent binding of both the antibody and the lectin. A crude leishmanial lipid extract readily bound these three reagents, suggesting that at least part of these epitopes are of a glycolipid nature. These Gal alpha 1----3Gal epitopes may thus serve as an antigenic source for the excess production of anti-Gal. In view of the naturally high level of anti-Gal in humans and its binding to T. cruzi and Leishmania, it is argued that these antibodies may contribute to the natural defense against the invasion of such parasites.
抗半乳糖(Anti-Gal)是一种天然抗体,在人血清中浓度异常高。它占循环IgG的1%,对Galα1----3Gal碳水化合物表位具有独特的特异性。在本研究中,我们发现恰加斯病(Chagas' disease)和利什曼原虫感染患者血清中的抗半乳糖滴度比健康或细菌感染个体高10倍和16倍。抗半乳糖滴度的这种增加似乎是针对寄生性Galα1----3Gal表位的特异性免疫反应的结果。亲和层析纯化的抗半乳糖抗体与克氏锥虫(Trypanosoma cruzi)和美洲利什曼原虫(American Leishmania)寄生虫的结合研究确实证明了这些寄生虫上存在Galα1----3Gal表位。这一发现得到了另外两种识别Galα1----3Gal的分子与寄生虫结合的支持:单克隆抗体Gal-13和凝集素,即简单叶豆凝集素(Bandeiraea simplicifolia I B4)。此外,半乳糖而非葡萄糖可抑制抗半乳糖抗体和简单叶豆凝集素I B4的结合。另外,用α-半乳糖苷酶预处理去除寄生虫末端的α-半乳糖基残基,或用过碘酸盐氧化结合表位,可阻止抗体和凝集素随后的结合。粗制的利什曼原虫脂质提取物很容易结合这三种试剂,表明这些表位至少部分具有糖脂性质。因此,这些Galα1----3Gal表位可能是抗半乳糖过量产生的抗原来源。鉴于人类抗半乳糖的天然高水平及其与克氏锥虫和利什曼原虫的结合,有人认为这些抗体可能有助于对这类寄生虫入侵的天然防御。